Christopher Koh

HBsAg kinetics in chronic hepatitis D during interferon therapy: on‐treatment prediction of response

Mouse models of acute and chronic hepacivirus infection

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

Middle-aged individuals may be in a perpetual state of H3N2 influenza virus susceptibility

Genetic determinants of hepatic steatosis in man

Enhancing extracellular vesicle cargo loading and functional delivery by engineering protein-lipid interactions

Innate Lymphoid Cell Interactions with Microbiota: Implications for Intestinal Health and Disease

SEC14L2 enables pan-genotype HCV replication in cell culture

Interactions between the microbiota, immune and nervous systems in health and disease

Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment

Genetic modifiers of non-alcoholic fatty liver disease progression

The Effect of PNPLA3 on Fibrosis Progression and Development of Hepatocellular Carcinoma: A Meta-analysis

Liver transplantation and non-alcoholic fatty liver disease

PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals

Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease

Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease

Mouse patatin-like phospholipase domain-containing 3 influences systemic lipid and glucose homeostasis

New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus

Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome

The Role of Cholesterol in the Pathogenesis of NASH

Lonafarnib: First Approval

Hallmarks of aging: An expanding universe

Interferon-α–Induced TRAIL on Natural Killer Cells Is Associated With Control of Hepatitis C Virus Infection

Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir

Type I interferons in infectious disease

Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The Multiple Parallel Hits Hypothesis

A Humanized Mouse Model to Study Hepatitis C Virus Infection, Immune Response, and Liver Disease

Incidence of non-alcoholic fatty liver disease in Hong Kong: A population study with paired proton-magnetic resonance spectroscopy

Interferon α–Stimulated Natural Killer Cells From Patients With Acute Hepatitis C Virus (HCV) Infection Recognize HCV-Infected and Uninfected Hepatoma Cells via DNAX accessory molecule-1

Genome-Wide Association Study Identifies Variants Associated With Histologic Features of Nonalcoholic Fatty Liver Disease

Pharmacology and therapeutic potential of interferons

Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner

In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression

What are the pros and cons of the use of host-targeted agents against hepatitis C?

A predictive model for carcinogenesis in patients with chronic hepatitis B undergoing entecavir therapy and its validation

Role of the Microbiota in Immunity and Inflammation

Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome

The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population

Role of the gut microbiota in immunity and inflammatory disease

Mechanisms of NAFLD development and therapeutic strategies

Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study

Non-alcoholic fatty liver disease

Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association

Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD)

Immune Responses to HCV and Other Hepatitis Viruses

Crohn's disease

Extinction of Hepatitis C Virus by Ribavirin in Hepatoma Cells Involves Lethal Mutagenesis

The genetics of NAFLD

Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease

Chronic hepatitis B

Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016

Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis

Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells

Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study

Updated Clinical Classification of Pulmonary Hypertension

Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma

Intestinal epithelial cells: regulators of barrier function and immune homeostasis

Hepatitis B virus infection

The global NAFLD epidemic

Toward Genetic Prediction of Nonalcoholic Fatty Liver Disease Trajectories: PNPLA3 and Beyond

Mechanisms for Insulin Resistance: Common Threads and Missing Links

Advances in Pediatric Nonalcoholic Fatty Liver Disease†

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms

Innate lymphoid cells — a proposal for uniform nomenclature

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ).

Revisiting STAT3 signalling in cancer: new and unexpected biological functions

Type I Interferon Protects Antiviral CD8+ T Cells from NK Cell Cytotoxicity

Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study

NF-κB, inflammation, immunity and cancer: coming of age

Experimental models to study the immunobiology of hepatitis C virus

Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent From Interferons

Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis

Real-World Evidence — What Is It and What Can It Tell Us?

Humanized mice efficiently engrafted with fetal hepatoblasts and syngeneic immune cells develop human monocytes and NK cells

Hepatocellular Carcinoma

Biomarkers of Inflammation and Coagulation Are Associated With Mortality and Hepatitis Flares in Persons Coinfected With HIV and Hepatitis Viruses

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Mechanisms of Insulin Action and Insulin Resistance

Control of Human Viral Infections by Natural Killer Cells

Will There Be a Vaccine to Prevent HCV Infection?

Characterization of nonprimate hepacivirus and construction of a functional molecular clone

Acute Liver Damage Associated with Innate Immune Activation in a Small Nonhuman Primate Model of Hepacivirus Infection

Global distribution and prevalence of hepatitis C virus genotypes

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1

Cytokine Storm

Dissociation betweenAPOC3variants, hepatic triglyceride content and insulin resistance

A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes

Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome

Steatosis and Steatohepatitis: Complex Disorders

CD4 + T-cell subsets in inflammatory diseases: beyond the T h 1/T h 2 paradigm

First international external quality assessment for hepatitis delta virus RNA quantification in plasma

Patatin‐Like Phospholipase Domain‐Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population

Fibrosis — A Common Pathway to Organ Injury and Failure

Protein Lipidation: Occurrence, Mechanisms, Biological Functions, and Enabling Technologies

Human Fatty Liver Disease: Old Questions and New Insights

Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus

Viral persistence, liver disease, and host response in a hepatitis C–like virus rat model

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Exploring the ethical and regulatory issues in pragmatic clinical trials

Characterization of Human Antiviral Adaptive Immune Responses during Hepatotropic Virus Infection in HLA-Transgenic Human Immune System Mice

Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment

Nonalcoholic Fatty Liver Disease

Microbial Translocation Across the GI Tract

Heterogeneity of Human CD4⁺T Cells Against Microbes

Liver stiffness‐based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy

Long-term therapy of chronic delta hepatitis with peginterferon alfa

Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV‐1 study

What is the future of ribavirin therapy for hepatitis C?

Hematopoietic prostaglandin D synthase defines a proeosinophilic pathogenic effector human TH2 cell subpopulation with enhanced function

Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial

Natural Killer Cells Are Polarized Toward Cytotoxicity in Chronic Hepatitis C in an Interferon-Alfa–Dependent Manner

The Association of Genetic Variability in Patatin-Like Phospholipase Domain-Containing Protein 3 (PNPLA3) with Histological Severity of Nonalcoholic Fatty Liver Disease†

Ribavirin Improves Early Responses to Peginterferon Through Improved Interferon Signaling

Host Response to Translocated Microbial Products Predicts Outcomes of Patients With HBV or HCV Infection

Sequence Analysis of Hepatitis C Virus From Patients With Relapse After a Sustained Virological Response: Relapse or Reinfection?

Early Multiphasic HBV Infection Initiation Kinetics Is Not Clone-Specific and Is Not Affected by Hepatitis D Virus (HDV) Infection

Long‐term lamivudine therapy in chronic hepatitis B

Important Factors in Reliable Determination of Hepatitis C Virus Genotype by Use of the 5′ Untranslated Region

AASLD clinical practice guidelines: A critical review of scientific evidence and evolving recommendations

A Phase 2 Study of Peginterferon Lambda, Lonafarnib and Ritonavir for 24 Weeks: End-of-Treatment Results from the LIFT HDV Study

Long‐term outcome of chronic hepatitis C after sustained virological response to interferon‐based therapy

Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon‐alpha therapy via mathematical modeling

A phase 2 study exploring once daily dosing of ritonavir boosted lonafarnib for the treatment of chronic delta hepatitis – end of study results from the LOWR HDV-3 study